Early indicators of infection; SARS-CoV2 [COVID-19]
Research type
Research Study
Full title
Potential of physiological and biological signatures in the early identification of infectious disease, such as COVID-19
IRAS ID
285518
Contact name
Steve Emmett
Contact email
Sponsor organisation
Defence Science and Technology Laboratories
Clinicaltrials.gov Identifier
1052Int20, DSTL_Ref
Duration of Study in the UK
1 years, 5 months, 28 days
Research summary
This is a prospective observational cohort study that will follow service personnel (permanent staff, recruits and directing staff) entering return to work or a period of collective training.\n\nThis is a two phase study: \nPhase 1 – pilot study to examine feasibility of remote physiological data capture (over 2 weeks), including 6 weeks biological sample collection. \nPhase 2 – six weeks of both physiological data collection and biological sample collection.\n\nAs part of clinical risk mitigation during the current COVID-19 pandemic, a worker testing regimen has been implemented at the investigator site as a force protection measure. This study will undertake participant physiological monitoring and laboratory-based sample analysis to understand (i) the rates of infection (and development of SARS-CoV2 antibodies - seroconversion) during MOD return to work, (ii) establish the value of the presence of antibodies in the blood of individuals via serological testing, (iii) identify early physiological correlates of infection and (iv) predict disease severity through biochemical and transcriptomic (gene)/proteomic (protein) analysis.\n\nThis study should be undertaken during the acute phase of the current pandemic as part of the return to work recovery phase and during any future high prevalence periods. If delayed, background prevalence rates of SARS-CoV2 may become too low and would require significantly larger and burdensome cohort studies.\n
REC name
N/A
REC reference
N/A